Batten Disease Foundation (BBDF) is focused on accelerating research
to find a cure for Batten disease.
As part of its mission, BBDF is partnering with the Alzheimer’s Drug
Discovery Foundation to sponsor 20-25 clinician scientists and
investigators in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) research
to attend ADDF’s 5th Drug Discovery in Neurodegeneration: An
Intensive Course on Translating Research into Drugs immediately
followed by a one-day conference focused exclusively on Drug Discovery
goals of the combined Course and Conference are:
education in drug discovery for neurodegeneration;
identification and prioritization of key targets in JNCL drug discovery;
the initiation of an international dialogue in JNCL drug discovery; and
the creation of international strategic partnerships, collaborations,
resources and other opportunities that move JNCL basic science research
into drug discovery.
Driving treatment-oriented research in JNCL through education,
collaboration and resource partnerships with key thought leaders in
emerging areas are just a few of BBDFs strategies to cure JNCL.
APPLICATION TO ATTEND:
If you would like to apply for acceptance
to attend the 5th Drug Discovery in Neurodegeneration: An Intensive
Course on Translating Research into Drugs in San Diego, California,
February 6-8, 2011, immediately followed by the Drug Discovery in
JNCL Conference on February 9, 2011, please fill out a copy of the
application and email it in WORD format to Danielle M. Kerkovich, PhD,
Scientific Consultant to Beyond Batten Disease Foundation at
no later than December 17, 2010.
Space is limited to less than 25 and acceptance will be based upon
your identification of potential drug targets in JNCL and your
ability/interests in contributing to a global effort in JNCL drug
If accepted, BBDF will pay for your air travel, accommodations and
Your attendance at the entire Course and Conference, and a
three-part Webinar tutorial on JNCL will be required.
Local travel and any meals outside of the Course and Conference will
be the responsibility of each participant.
If you have any questions, please contact
Dr. Kerkovich at
(preferred) or by phone at +1-202-812-6462. Please share this
information with your colleagues.
Together with NCL-Stiftung, our German-based colleagues, and the Batten
Disease Support and Research Association (BDSRA), BBDF is driving
policy, creating strategic partnerships, identifying much-needed
physical and intellectual resources, and recruiting talented
investigators to join us in the fight against JNCL.
Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity
solely dedicated to rapidly accelerating the discovery and development
of drugs to prevent, treat and cure Alzheimer’s disease, related
dementias and cognitive aging. In addition to supporting the Alzheimer’s
and related disorders, ADDF expanded their efforts in 2006 to share drug
discovery education and awareness with academic researchers and
clinician scientists in Parkinson’s Disease, Multiple Sclerosis,
Amyolateral Sclerosis (ALS). BBDF is proud and thankful for its
partnership with ADDF which adds Lysosomal Storage Disease to this list.